Disposition of clozapine in man: lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms.

British Journal of Clinical Pharmacology

Volumn 37, Issue 1, 1994, Pages 71-74

  Dahl, ML ^a   Llerena, A ^a   Bondesson, U ^a   Lindstrom, L ^a   Bertilsson, L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DEBRISOQUINE; MEPHENYTOIN; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIOAVAILABILITY; CAUCASIAN; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG OXIDATION; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; SEDATION; SIDE EFFECT; VERTIGO; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; CLOZAPINE; DEBRISOQUIN; FEMALE; HUMAN; HYDROXYLATION; MALE; MEPHENYTOIN; MIDDLE AGE; POLYMORPHISM (GENETICS); SUPPORT, NON-U.S. GOV'T; SWEDEN; TISSUE DISTRIBUTION;

EID: 0028307888     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1994.tb04242.x     Document Type: Article

References (32)

1. Clozapine for the treatment‐resistant schizophrenic. A double‐blind comparison with chlorpromazine
2. Clozapine. A novel antipsychotic agent
3. The metabolism of 8‐chloro‐11‐(4‐methyl‐1‐piperazinyl)‐5H‐dibenzo[b, e][1,4]diazepine (clozapine) in mice, dogs and human subjects
4. 3‐ bei der Metabolisierung des Clozapine im menschlichen Körper
5. Clozapine treatment of schizophrenic patients. Plasma concentration and coagulation factors
6. Determination of clozapine and its N‐demethylated metabolite in plasma by use of gas chromatography‐mass spectrometry with single ion detection
7. Clinical pharmacokinetics of clozapine in chronic schizophrenic patients
8. Dose‐related plasma levels of clozapine: influence of smoking behaviour, sex and age
9. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings
10. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans
11. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype
12. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
13. Genetically variable metabolism of antidepressants and neuroleptic drugs in man
14. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population
15. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects
16. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man
17. Genetic polymorphism of S‐mephenytoin hydroxylation
18. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin
19. Polymorphic hydroxylation of debrisoquine in man
20. Determination of debrisoquine and its 4‐hydroxy metabolite in biological fluids by gas chromatography with flame‐ionization and nitrogen selective detection
21. S‐mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin
22. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6
23. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4‐hydroxylation
24. 3H) GBR‐12935 binding proteins
25. Debrisoquine/sparteine monooxygenase and other P450s in brain
26. 4
27. Evidence for a role of haloperidol‐sensitive sigma‐“opiate” receptors in the motor effects of antipsychotic drugs
28. Is the sigma opiate receptor a proadifen‐sensitive subform of cytochrome P‐450
29. 3H)dextromethorphan and ó ligands to guinea pig brain
30. Role of genetic polymorphism in psychopharmacology—an update
31. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia
32. Multiple‐dose pharmacokinetics of clozapine in patients